Lantern Pharma is a biotechnology company, focused on utilizing artificial intelligence, machine learning and genomic data. Co.'s drug candidates include: LP-300, which is a cysteine-modifying molecular entity that works to modulate multiple cellular pathways and is a combination agent for targeted indications in non-small cell lung cancer; LP-184, which preferentially damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways; LP-284, which is for the treatment of several non-Hodgkin's lymphomas including mantle cell lymphoma and double hit lymphoma; and LP-100, which exploits cancer cells' deficiency in DNA repair mechanisms. The LTRN average annual return since 2020 is shown above.
The Average Annual Return on the LTRN average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LTRN average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LTRN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|